Accès membre

Nos publications

Publications FILO LLC-MW (formerly FCGCLL-WM and GOELAMS Intergroup) | 2012-2018

Note « méthodologique »

Les publications retenues dans ce listing sont celles qui sont signées par au moins trois auteurs appartenant à des centres différents et qui peuvent alors refléter l’activité du groupe.   

Sont donc exclues les publications dont les auteurs appartiennent au même centre : exclusion d’un certain nombre de travaux monocentriques de la Pitié Salpétrière, de Bobigny, de Toulouse, de Lyon ou de Caen par exemple.

Ne figurent pas non plus les différentes publications de l’ERIC (évaluation de p53, analyse du statut IGHV, étude phénotypique de la MRD, …) car elles sont habituellement co-signées par un seul auteur de l’intergroupe (voire deux mais alors du même centre).

Les abstracts de congrès ne sont pas listés.

 

2012

 

-Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

 

Blood 2012, 119: 5104-10. Epub 2012 Feb 14.

 

-Van Den Neste E, Letestu R, Aurran-Schleinitz T, Ysebaert L, Feugier P, Leprêtre S, Dartigeas C.

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

 

Leukemia & Lymphoma 2012, 53 :362-70. Epub 2011 Sep 19.

 

-Michallet AS, Feugier P, Delmer A, Ysebaert L, Cazin B, Dartigeas C, Fornecker L, Van Den Neste E, Cymbalista F, Lévy V, Leblond V, Troussard X.

Specific treatment modalities for elderly patients with chronic lymphocytic leukemia.

 

Aging Health 2012, 8: 317-22.

 

-Guièze R, Ysebaert L, de Guibert S, Dhédin N, Bay JO, Troussard X, Tournilhac O.

Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia.

 

Bulletin du Cancer 2012, 99 : 1123-32. Review. French.

 

2013

 

-Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG.

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

 

Journal of Clinical Oncology 2013, 31: 301-7. Epub 2012 Dec 10.

 

-Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblond V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW); Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS); Groupe d’Etude des Lymphomes de l’Adulte (GELA).

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Haematologica 2013, 98 : 649-54. Epub 2012 Oct 12.

 

-Michallet AS, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, Salles G, Coiffier B, Laurent G, Ysebaert L.

First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.

Journal of Geriatric Oncology 2013, 4:141-7. Epub 2013 Feb 26.

 

-Bouvet E, Borel C, Obéric L, Compaci G, Cazin B, Michallet AS, Laurent G, Ysebaert L.

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.

Haematologica 2013, 98: 65-70. Epub 2012 Oct 12.

 

 -Aurran T, Callet-Bauchu E, Cymbalista F, Delmer A, Dreyfus B, Nguyen Khac F, Leblond V, Lepretre S, Levy V, Raynaud S, Troussard X. 
Recommandations 2012 de la SFH pour le diagnostic, le traitement et le suivi de la leucémie lymphoïde chronique.

Hématologie 2013, 19 (supplément 1) : 4-9. DOI : 10.1684/hma.2012.0744

 

-Cazin B, Chaibi P, Cymbalista F, Delmer A, Feugier P, Fornecker L, Leblond V, Levy V,  Michallet AS, Moulin B, Pegourie B, Sebbane G, Soubeyran P, Troussard X, Zini JM. 

Prise en charge de la leucémie lymphoïde chronique chez les patients âgés.

Hématologie 2013, 19 (supplément 1) : 10-20. DOI : 10.1684/hma.2012.0743

 

-Cazin B, Delmer A, Cymbalista F, Leblond V, Letestu R, Lévy V, Tournilhac O, Troussard X.

Leucémie lymphoïde chronique.

EMC - Hématologie 2013, 8: 1-15 [article 13-013-B-20]

 

2014

-Cornet E, Tomowiak C, Tanguy-Schmidt A, Lepretre S, Dupuis J, Feugier P, Devidas A, Mariette C, Leblond V, Thiéblemont C, Validire-Charpy P, Sutton L, Gyan E, Eisenmann JC, Cony-Makhoul P, Ysebaert L, Troussard X; Société Française d'Hématologie.

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.

British Journal of Haematology 2014, 166 : 390-400. Epub 2014 Apr 18.

 

-Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Annals of Hematology 2014, 93: 1977-83. Epub 2014 Jul 5.

 

-Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X.

Recommandations 2014 de la Société Française d’Hématologie pour le diagnostic, le traitement et le suivi de la leucémie à tricholeucocytes

Hématologie 2014, 20 : 200-6. doi : 10.1684/hma.2014.0953

 

2015

 

-Durot E, Michallet AS, Leprêtre S, Le QH, Leblond V, Delmer A.

Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study.

European Journal of Haematology 2015, 95 : 160-7. Epub 2015 Jan 21.

 

-Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A.

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).

American Journal of Hematology 2015, 90: 204-7. Epub 2015 Jan 16.

 

-Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

American Journal of Hematology 2015, 90 : 511-4. Epub 2015 Apr 1.

 

-Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A.

Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Annals of Hematology 2015, 94: 89-95. Epub 2014 Sep 7.

 

-Ysebaert L, Feugier P, Michallet AS.

Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies.

Current Opinion in Oncology 2015, 27: 365-70.

 

-Dupuis J, Brice P, François S, Ysebaert L, de Guibert S, Levy V, Leprêtre S, Choquet S, Dilhuydy MS, Fornecker L, Morel V, Tempescul A.

Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.

Clinical Lymphoma Myeloma & Leukemia 2015, 15 :e43-46. Epub 2014 Aug 1.

 

-Guièze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, Nguyen-Khac F, Davi F, Véronèse L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Béral H, Alsolami R, Hamblin A, Mason J, Pettitt A, Hillmen P, Taylor J, Knight SJ, Tournilhac O, Schuh A.

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Blood 2015, 126 : 2110-7. Epub 2015 Aug 27.

 

-Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, Corby A, Aurran-Schleinitz T, Gastaud L, Talbot A, Leprêtre S, Mahe B, Payet C, Soussain C, Bonnet C, Vincent L, Lissandre S, Herbrecht R, Kremer S, Leblond V, Fornecker LM.

Bing-Neel syndrome, a rare complication of Waldenström's macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Haematologica 2015, 100 : 1587-94. Epub 2015 Sep 18.

 

2016

 

-Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Leukemia & Lymphoma 2016, 57 : 328-34. Epub 2015 Sep 28.

 

-Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G.

Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.

Leukemia & Lymphoma 2016, 57 : 852-65. Epub 2015 Oct 8.

 

-Gagez AL, Tuaillon E, Cezar R, Dartigeas C, Mahé B, Letestu R, Maisonneuve H, Gouilleux-Gruart V, Bollore K, Ferrant E, Aurran T, Feugier P, Leprêtre S, Cartron G.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

Blood Cancer Journal 2016,6:e389. Epub 2016 jan 22.

 

-Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B, Tournilhac O, Boubaya M, Vargaftig J, Choquet S, Leblond V; FILO (French Innovative Leukemia Organization).

Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.

American Journal of  Hematology 2016, 91 : 782-6. Epub 2016 Jun 3.

 

-Wanquet A, Birsen R, Lemal R, Hunault M, Leblond V, Aurran-Schleinitz T.

Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

Blood 2016, 127 : 2356-8. Epub 2016 Mar 18.

 

-Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

British Journal of Haematology 2016, 175 : 462-6. Epub 2016 Sep 9.

 

-Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Hematological Oncology 2016 Nov 22. doi: 10.1002/hon.2370.

 

2017

 

-Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

British Journal of Haematology 2017, 176 : 37-49. Epub 2016 Nov 11.

 

-Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G,      Apparailly F.

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Haematologica 2017, 102 : 746-54. Epub 2017 Jan 25.

 

-Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leukemia & Lymphoma 2017, 58 : 2615-23. Epub 2017 Apr 10.

 

-Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

American Journal of  Hematology 2017, 92 : E105-E107. Epub 2017 Apr 29.

 

-Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Clinical Pharmacokinetics 2017, 56 : 635-47.

 

-Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS, Tournilhac O, Dupuis J, Sinet P, Albrecht C, Cymbalista F.

Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.

American Journal of  Hematology 2017, 92 : E166-E168. Epub 2017 May 30. 

 

-Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA, Nguyen-Khac F.

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.

Leukemia 2017, 31: 1625-9. Epub 2017 Mar 27.

 

-Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

British Journal of Haematology 2017, 179:439-48. Epub 2017 Aug 2.

 

-Steinbrecher D, Chelliah Jebaraj BM, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S.

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.

Leukemia & Lymphoma 2017, Oct 24 [Epub ahead of print]

 

2018

-Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

American Journal of Hematology 2018, 93: E24-E27. Epub 2017 Nov 17.

 

-Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Lancet Haematology 2018, 5: e82-e94. Epub 2017 Dec 20.

 

-Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

American Journal of Hematology 2018, 93: E52-E54. Epub 2017 Dec 4. 

 

-Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, Le Garff-Tavernier M, Bougacha N, Struski S, Bidet A, Laharanne E, Barin C, Veronese L, Prié N, Eclache V, Gaillard B, Michaux L, Lefebvre C, Gaillard JB, Terré C, Penther D, Bastard C, Nadal N, Fert-Ferrer S, Auger N, Godon C, Sutton L, Tournilhac O, Susin SA, Nguyen-Khac F; GroupeFrancophone de Cytogénétique Hématologique (GFCH) and the French Innovative Leukemia Organization (FILO) group.

"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.

American Journal of Hematology 2018, 93: 375-82. Epub 2017 Dec 18.

 

-Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V.

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Haematologica 2018 Feb 1 [Epub ahead of print]

 

-Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Blood 2018 Feb 1 [Epub ahead of print]

 

-Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurrant T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournihac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Increased rituximab exposure does not improve response and outcome of CLL patients after FCR. A French Innovative Leukemia Organization (FILO) Study.

Haematologica 2018 Mar 8 [Epub ahead of print] 

 

-Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van den Neste E, Béné MC, Cymbalista F, Roos-Weil D, Leprêtre S.

Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Haematologica 2018 Mar 15 [Epub ahead of print] 

 

-Pigneux A, Bene MC, Salmi LR, Dumas PY, DElaunay J, Bonmati C, Guieze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard Mn Jourdan E, Vey N, Zerazhi H, Hisri Y, Mineur A, Aselineau J, Delepine R, Cahn JY, Ifrah N, Reher C.

Improved survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With Unfavorable Cytogenetics : Results of the LAM-SA 2007 FILO Trial

J Clin Oncol.2018 Sep27:JCO2018787366. doi :10.1200/JCO.2018.78.7366 [Epub ahead of print)